THE MULTIMODAL DRUG APPROACH – A SINGLE ACTIVE INGREDIENT WITH MULTIPLE EFFECTS:

The therapeutic approach to drug development has changed in recent years to reflect awareness of the parallel effects of medications and the multifactoral nature of certain disorders, such as cardiometabolic disease.

Traditionally, drugs were developed to act on a single therapeutic target and thus patients with several risk factors had a heavy pill burden, leading to compliance, efficacy and drug-drug interaction issues.

The beginning of the 2000s saw the emergence of the 'polypill', which combines several active ingredients in one single tablet and aims to reduce the number of medications to be taken. This allows improved dosage control and better patient compliance. However,  the full scale uptake of this approach is hampered by complex pharmaceutical development and registration and further drug-drug interactions.

Genfit’s scientific vision is to treat multiple risk factors for cardiometabolic disease simultaneously with a single, active compound. This is known as a 'multimodal' drug approach. Multimodal drugs are investigated to cure several conditions with a unique active ingredient, resulting in fewer drug-drug interactions, better patient compliance and thus an improved efficacy/safety ratio. Several multimodal drugs developed by Genfit are currently in clinical phases as presented in our Pipeline.